ES2346774T3 - Analogos de 17,20(z)-deshidro vtamina d y sus usos. - Google Patents

Analogos de 17,20(z)-deshidro vtamina d y sus usos. Download PDF

Info

Publication number
ES2346774T3
ES2346774T3 ES05849730T ES05849730T ES2346774T3 ES 2346774 T3 ES2346774 T3 ES 2346774T3 ES 05849730 T ES05849730 T ES 05849730T ES 05849730 T ES05849730 T ES 05849730T ES 2346774 T3 ES2346774 T3 ES 2346774T3
Authority
ES
Spain
Prior art keywords
group
hydroxy
hydrogen
baselineskip
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05849730T
Other languages
English (en)
Spanish (es)
Inventor
Hector F. Deluca
Bulli Padmaja Tadi
Lori A. Plum
Margaret Clagett-Dame
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2346774T3 publication Critical patent/ES2346774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
ES05849730T 2004-11-22 2005-11-18 Analogos de 17,20(z)-deshidro vtamina d y sus usos. Expired - Lifetime ES2346774T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63000704P 2004-11-22 2004-11-22
US630007P 2004-11-22

Publications (1)

Publication Number Publication Date
ES2346774T3 true ES2346774T3 (es) 2010-10-20

Family

ID=36216285

Family Applications (3)

Application Number Title Priority Date Filing Date
ES05849730T Expired - Lifetime ES2346774T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(z)-deshidro vtamina d y sus usos.
ES05851805T Expired - Lifetime ES2347058T3 (es) 2004-11-22 2005-11-18 2-metilen-19-nor-1(alfha)-hydroxy-17-eno-hemopregnacalciferol y sus usos.
ES05851757T Expired - Lifetime ES2344989T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(e)-deshidro vitamina d y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES05851805T Expired - Lifetime ES2347058T3 (es) 2004-11-22 2005-11-18 2-metilen-19-nor-1(alfha)-hydroxy-17-eno-hemopregnacalciferol y sus usos.
ES05851757T Expired - Lifetime ES2344989T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(e)-deshidro vitamina d y sus usos.

Country Status (11)

Country Link
US (6) US7241750B2 (https=)
EP (3) EP1828114B1 (https=)
JP (3) JP2008520705A (https=)
AT (3) ATE465144T1 (https=)
AU (3) AU2005309790B2 (https=)
CA (3) CA2588401C (https=)
DE (3) DE602005021702D1 (https=)
ES (3) ES2346774T3 (https=)
MX (3) MX2007006261A (https=)
NZ (3) NZ555278A (https=)
WO (3) WO2006057885A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US8404667B2 (en) 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
MX2007006261A (es) 2004-11-22 2007-07-10 Wisconsin Alumni Res Found Analogos de 17,20(z)-deshidro vitamina d y sus usos.
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
WO2008091686A2 (en) * 2007-01-25 2008-07-31 Bioxell S.P.A. SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
US20120237472A1 (en) * 2009-07-24 2012-09-20 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
EP2525799B1 (en) * 2009-10-02 2014-09-03 Wisconsin Alumni Research Foundation (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
CA2793727C (en) * 2010-03-23 2017-01-03 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
CA2851283C (en) * 2011-10-21 2020-07-14 Wisconsin Alumni Research Foundation 2-methylene-vitamin d analogs and their uses

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
US5362719A (en) 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
ES2070307T3 (es) 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
EP0717034B1 (en) 1994-12-14 1999-04-07 Duphar International Research B.V Vitamin D compounds and method of preparing these compounds
GB9625271D0 (en) * 1996-12-04 1997-01-22 Leo Pharm Prod Ltd Chemical compounds
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
KR100593238B1 (ko) 1997-06-25 2006-06-26 데이진 가부시키가이샤 비타민 ｄ3 유도체 및 이로부터 제조된 염증성 호흡기 질환 치료제
GB9721156D0 (en) * 1997-10-06 1997-12-03 Leo Pharm Prod Ltd Novel vitamin d analogues
WO1999049870A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
NZ522909A (en) * 2000-05-31 2004-09-24 Wisconsin Alumni Res Found 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
EP1301479A2 (en) * 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
NZ524657A (en) * 2000-09-08 2004-12-24 Wisconsin Alumni Res Found 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
ATE410172T1 (de) 2001-05-22 2008-10-15 Bioxell Spa Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
HK1079766B (zh) * 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
MXPA06005887A (es) 2003-11-25 2006-06-27 Wisconsin Alumni Res Found Analogos de vitamina d para la prevencion y el tratamiento de la obesidad.
EP1694333A2 (en) 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
MX2007006261A (es) * 2004-11-22 2007-07-10 Wisconsin Alumni Res Found Analogos de 17,20(z)-deshidro vitamina d y sus usos.
AU2005309789A1 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
WO2008035207A2 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
DK2148684T3 (da) * 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens

Also Published As

Publication number Publication date
MX2007006262A (es) 2007-07-10
CA2588396A1 (en) 2006-06-01
AU2005309805B2 (en) 2011-06-09
US20070259838A1 (en) 2007-11-08
JP5161582B2 (ja) 2013-03-13
US20060111330A1 (en) 2006-05-25
CA2588396C (en) 2013-04-23
US7241748B2 (en) 2007-07-10
DE602005020842D1 (de) 2010-06-02
EP1828114B1 (en) 2010-04-21
MX2007006546A (es) 2007-08-17
JP2008520704A (ja) 2008-06-19
NZ555277A (en) 2010-12-24
WO2006057885A2 (en) 2006-06-01
US8232263B2 (en) 2012-07-31
US7241750B2 (en) 2007-07-10
ES2344989T3 (es) 2010-09-13
EP1846370A2 (en) 2007-10-24
CA2588410A1 (en) 2006-06-01
DE602005021702D1 (de) 2010-07-15
EP1817279A2 (en) 2007-08-15
WO2006057901A3 (en) 2006-07-13
ATE469883T1 (de) 2010-06-15
AU2005309806B2 (en) 2012-03-08
EP1828114A2 (en) 2007-09-05
WO2006057900A2 (en) 2006-06-01
MX2007006261A (es) 2007-07-10
NZ555282A (en) 2010-12-24
WO2006057885A3 (en) 2006-06-29
US7241752B2 (en) 2007-07-10
US20070249569A1 (en) 2007-10-25
CA2588410C (en) 2013-04-02
EP1846370B1 (en) 2010-06-02
JP5043673B2 (ja) 2012-10-10
US7741313B2 (en) 2010-06-22
ATE469127T1 (de) 2010-06-15
US20060111321A1 (en) 2006-05-25
WO2006057900A3 (en) 2006-07-06
JP2008520690A (ja) 2008-06-19
US20060116351A1 (en) 2006-06-01
ES2347058T3 (es) 2010-10-25
US7704982B2 (en) 2010-04-27
EP1817279B1 (en) 2010-05-26
NZ555278A (en) 2010-12-24
AU2005309805A1 (en) 2006-06-01
ATE465144T1 (de) 2010-05-15
AU2005309790B2 (en) 2012-03-08
JP2008520705A (ja) 2008-06-19
US20070249568A1 (en) 2007-10-25
DE602005021538D1 (de) 2010-07-08
WO2006057901A2 (en) 2006-06-01
CA2588401A1 (en) 2006-06-01
AU2005309806A1 (en) 2006-06-01
CA2588401C (en) 2013-02-12
AU2005309790A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
ES2339401T3 (es) Analogo de vitamina d-nel, metodos y usos del mismo.
ES2339402T3 (es) Analogo de vitamina d - rak, metodos y usos del mismo.
ES2274116T3 (es) 1-alfa-hidroxi-2-metilenj-19-nor-pregnacalciferol y sus usos.
ES2206893T3 (es) Compuestos de 2-alquil-19-nor-vitamina d.
ES2227215T3 (es) 1 alfa-hidroxi.2.metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.
ES2314190T3 (es) (20s)-1alfa-hidroxi-2-alfa-metil y 2beta-metil-19-nor-vitamina d3 y sua usos.
ES2291305T3 (es) Compuestos 2-alquiliden-19-nor-vitamina d y sus usos terapeuticos.
US8232263B2 (en) 17,20(Z)-dehydro vitamin D analogs and their uses
ES2420682T3 (es) Compuestos tipo 26,27-homologada-20-epi-2-alquil-19-nor-vitamina D
ES2387714T3 (es) Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D
ES2545403T3 (es) (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3
ES2349662T3 (es) 2-metileno-18,19-dinor-1alfa-hidroxi-homopregnacalciferol y sus usos.
MX2008012671A (es) Analogos 1 a,25-dihidroxi- 19, 26,27-trinor vitamina d 2-sustituidos y sus usos.
ES2236830T3 (es) Derivados de la vitamina d3.
MXPA06011499A (es) Compuestos de 2-alquiliden-18, 19-dinor-vitamina d.
AU2009268508A1 (en) 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
AU2009268498A1 (en) 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
ES2277293T3 (es) 2-metilen-19-nor-20(s)-25-metil-1-alfa-hidroxicalciferol y sus usos.
ES2358914T3 (es) 2-metileno-19,21-dinor-1alfa-hidroxi-bishomopregnacalciferol.